The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Practice-changing highlights in MDS from ASH 2025: the VERONA trial and triplet combinations
Jennifer Marvin-Peek, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares the practice-changing highlights in myelodysplastic syndromes (MDS) from ASH 2025. Dr Marvin-Peek mentions the VERONA trial (NCT04401748), as well as studies investigating triplet regimens. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
This is a tough question because there’s so many good presentations being presented. I think one of the ones is, you know, the Verona study is something that we were really, really looking for the data for. And I think Dr Garcia-Manero, he just presented the results from that. And while it’s a negative trial, I do think that this will have a significant impact on the way that a lot of, you know, a lot of us practice, particularly in the high-risk MDS group with high blasts, you know, seeing that there wasn’t a survival benefit with the addition of venetoclax, I think that could have a huge impact on how patients are treated...
This is a tough question because there’s so many good presentations being presented. I think one of the ones is, you know, the Verona study is something that we were really, really looking for the data for. And I think Dr Garcia-Manero, he just presented the results from that. And while it’s a negative trial, I do think that this will have a significant impact on the way that a lot of, you know, a lot of us practice, particularly in the high-risk MDS group with high blasts, you know, seeing that there wasn’t a survival benefit with the addition of venetoclax, I think that could have a huge impact on how patients are treated. Similarly, I think a lot of the triplet studies are where a lot of people are looking to nowadays. And I think a lot of the presentations gave a lot of granular data as to kind of the dose reductions and the dose density that patients are being treated with. And so I think that this is really valuable information for people in the community looking to how can we safely deliver these regimens to patients. So I think those are some of the big, big highlights.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
